Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 7/20 | 0.37 |
| ▸ | AKT2 | P31751 | 7/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.35 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796221 | 0.86 | PRKCQ (0.43) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL4153901 | 0.85 | TNKS (0.40) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL4153895 | 0.85 | TNKS (0.40) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL4159713 | 0.85 | TNKS (0.40) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL4156276 | 0.85 | MAP3K11 (0.42) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL3664985 | 0.84 | TGFBR1 (0.47) | CYP3A4CYP2C8TGFBR1JAK1PIP4K2A | |
| SCHEMBL4161605 | 0.84 | MAP3K11 (0.43) | CYP3A4CYP2C8TGFBR1JAK1IKBKB | |
| SCHEMBL4158344 | 0.83 | TGFBR1 (0.48) | CYP3A4CYP2C8TGFBR1PIP4K2APIP4K2B | |
| SCHEMBL4150489 | 0.82 | TGFBR1 (0.47) | CYP3A4CYP2C8TGFBR1JAK1PIP4K2A | |
| SCHEMBL4158299 | 0.81 | TGFBR1 (0.45) | CYP3A4CYP2C8TGFBR1JAK1PIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CYP3A4 111/4885CYP2C8 1297/4885TGFBR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.